A trial looking at cediranib for ovarian cancer that has come back (ICON6) | Not Recruiting
A trial looking at cediranib for ov... | Not Recruiting
A trial looking at cediranib for ovarian cancer that has come back (ICON6)
ICON6 (International Collaborative Ovarian Neoplasm 6)
Trial Source

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Relapsed platinum-sensitive ovarian cancer
Prof Jonathan Ledermann
See all trial contact details
Primary Contact Details
Not Recruiting
Recruitment Status
ISRCTN68510403
Primary Trial ID Number

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
http://www.cancerhelp.org.uk/trials/a-trial-looking-at-standard-treatment-with-or-without-cediranib-for-ovarian-fallopian-tube-or-primary-peritoneal-cancer-that-has-come-back
Research Details
  • Current hypothesis as of 13/03/2015:
    That cediranib has an influence on progression-free survival when comparing patients receiving chemotherapy alone with patients receiving chemotherapy and cediranib (AZD2171).

    Previous hypothesis:
    Over three separate trial stages the study hypotheses are:

    Stage 1:
    That it is safe to add a once daily tablet of cediranib to standard platinum-based chemotherapy

    Stage 2:
    That cediranib has an influence on progression free survival when comparing patients receiving chemotherapy alone with patients receiving chemotherapy and cediranib (AZD2171)

    Stage 3:
    1. That cediranib has an effect on overall survival when taken at the same time as chemotherapy (placebo versus active), and when taken at the same time and then continued as a maintenance treatment (placebo versus active)
    2. If the first Stage 3 assessments shows the product is effective, that cediranib has an effect on overall survival when taken at the same time as chemotherapy compared with at the same time and then continued as a maintenance treatment
Phase
Phase III
Study Design
Randomised three-arm double-blind placebo-controlled multicentre phase III trial
Study Type
Interventional
Intervention

Current interventions as of 13/03/2015:
Patients in Arm A (the reference arm) will receive standard platinum-based chemotherapy plus a daily oral placebo tablet for the duration of the chemotherapy and then until protocol defined disease progression occurs.

Patients in Arm B (concurrent cediranib arm) will also receive standard chemotherapy plus daily oral cediranib during chemotherapy only, and then an oral daily placebo tablet until protocol defined disease progression or toxicity limiting treatment occurs.

Patients in Arm C (concurrent and maintenance cediranib arm) will also receive standard chemotherapy plus oral cediranib daily during chemotherapy and until protocol defined disease progression or toxicity limiting treatment occurs.

Previous interventions:
Patients in Arm A (the reference arm) will receive standard platinum-based chemotherapy plus a daily oral placebo tablet for the duration of the chemotherapy and then for up to 18 months from the time of randomisation, or until protocol defined disease progression occurs.

Patients in Arm B (concurrent cediranib arm) will also receive standard chemotherapy plus daily oral cediranib during chemotherapy only, and then an oral daily placebo tablet for up to 18 months from the time of randomisation, or until protocol defined disease progression or toxicity limiting treatment occurs.

Patients in Arm C (concurrent and maintenance cediranib arm) will also receive standard chemotherapy plus oral cediranib daily during chemotherapy and then continued for up to 18 months from the time of randomisation, or until protocol defined disease progression or toxicity limiting treatment occurs.

The starting dose of cediranib is 30 mg taken orally once daily. This will be down titrated if required on medical assessment to 20 mg and then 15 mg.

Intervention Type
Drug
Primary Outcome Measures
    Current primary outcome measures as of 13/03/2015:
    Progression-free survival (PFS) in arms A vs C

    Previous primary outcome measures:
    Stage 1: Safety
    Stage 2: Progression free survival
    Stage 3: Overall survival

    Data for the outcomes above will be collected approximately 3 weekly during chemotherapy, 6 weekly after chemotherapy up to 18 months, 3 monthly up to 3 years, 6 monthly during years 4 and 5, then annually until protocol defined disease progression or death.
Secondary Outcome Measures
    Current secondary outcome measures as of 13/03/2015:
    1. Progression-free survival (PFS) across arms A, B and C
    2. Overall survival (OS)
    3. Toxicity
    4. Quality of Life (QoL)

    Previous secondary outcome measures:
    Stage 1: None
    Stage 2: Overall survival and toxicity
    Stage 3: Progression free survival, toxicity and quality of life

    Quality of life assessment will be made using EORTC QLQ-C30 version 3 and EORTC QLQ-OV28. This information will be supplemented by health questionnaire EQ-5D. Other outcome measures will be assessed by clinical interview, blood tests and CT scans.

    Data for the outcomes above will be collected approximately 3 weekly during chemotherapy, 6 weekly after chemotherapy up to 18 months, 3 monthly up to 3 years, 6 monthly during years 4 and 5, then annually until protocol defined disease progression or death.
Publication(s)
2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/21878941
2013 results in: Ledermann J, Perren T, Raja F, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. Eur J Cancer 2013;49(Suppl. 3):S5 (LBA10).
2016 results in: http://www.ncbi.nlm.nih.gov/pubmed/27025186
Result Reports
Sorry, this information is not available
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Female
Age Range
Adult
Who Can Participate
Patient
Number of Participants
470
Participant Inclusion Criteria
    1. Females aged 18 years or older with previous histologically proven diagnosis of:
    1.1. Epithelial ovarian carcinoma
    1.2. Fallopian tube carcinoma
    1.3. Primary serous peritoneal carcinoma
    Relapsing more than 6 months after completion of first-line platinum-based chemotherapy
    2. Signed informed consent and ability to comply with the protocol
    3. Ability to commence treatment within 2 weeks of randomisation
    4. Computerised Tomography (CT) or Magnetic Resonance Imaging (MRI) proven relapsed disease, more than six months since completion of first-line platinum-based chemotherapy
    5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
    6. Life expectancy more than 12 weeks
    7. If there is a past history of a solid tumour, this must have been treated curatively more than five years ago with no evidence of recurrence
    8. Adequate bone marrow function
    8.1. Absolute Neutrophil Count (ANC) greater than or equal to 1.5 x 109/l
    8.2. Platelets (Plt) greater than or equal to 100 x 109/l
    8.3. Haemoglobin (Hb) greater than or equal to 9g/dl (can be post transfusion)
    9. Adequate liver function (within 14 days before randomisation)
    9.1. Serum bilirubin (BR) = 1.5 x Upper Limit of Normal (ULN)
    9.2. Serum transaminases = 2.5 x ULN
    10. Adequate renal function
    10.1. Serum creatinine = 1.5 ULN
    10.2. Urine dipstick for proteinuria less than 2+. If urine dipstick is greater than or equal to 2+ on two occasions more than one week apart then a 24 hour urine must demonstrate less than or equal to 1 g of protein in 24 hours
Participant Exclusion Criteria
    1. Non-epithelial ovarian cancer, including malignant mixed Mullerian tumours and mucinous carcinoma of the peritoneum
    2. Poorly controlled hypertension (persistently elevated >150/100 mmHg despite anti-hypertensive medication)
    3. History of inflammatory bowel disease (Crohn's disease or ulcerative colitis)
    4. Malignancies other than ovarian cancer within 5 years prior to randomisation, except for adequately treated carcinoma in situ of the cervix and/or basal cell skin cancer. Patients who have a past history of a solid tumour, treated curatively, more than five years prior to randomisation, with no evidence of recurrence, are still eligible to enter ICON6
    5. Previous radiotherapy within 21 days prior to randomisation
    6. Treatment with any other investigational agent within 30 days prior to entering this trial. Patients are still eligible for entry into ICON6 if they have received previous treatment for ovarian cancer with either bevacizumab, erlotinib, or a Cox-2 inhibitor as long as more than 30 days have elapsed since the last treatment
    7. Arterial thrombotic event (including Transient Ischaemic Attack [TIA], cerebrovascular accident [CVA) and peripheral arterial embolus) within the previous 12 months
    8. Gastrointestinal (GI) impairment that could affect ability to take, or adsorption of, oral medicines including sub acute or complete bowel obstruction
    9. Known hypersensitivity to AZD2171 or other Vascular Endothelial Growth Factor (VEGF) inhibitors
    10. Major surgery within 2 weeks before entry into the trial
    11. Significant haemorrhage of >30 ml in a single episode within 3 months or any haemoptysis
    12. Evidence of severe or uncontrolled cardiac disease
    12.1. Myocardial Infarct (MI) or unstable angina within 12 months
    12.2. New York Health Association (NYHA) = grade 2 Congestive Heart Failure (CHF)
    12.3. Cardiac ventricular arrhythmias requiring medication
    12.4. History of 2nd or 3rd degree atrioventricular conduction defects
    13. Prolonged QTc (corrected) interval of >470 msec on electrocardiogram (ECG), or a family history of long QT syndrome
    14. Persisting = Grade 2 CTC (Common Toxicity Criteria) toxicity (except alopecia and neuropathy) from previous anti-cancer treatment. If peripheral sensory or motor neuropathy = grade 2 then paclitaxel can be omitted from the chemotherapy at the discretion of the treating physician
    15. History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory in the case of suspected brain metastases. Spinal MRI is mandatory in the case of suspected spinal cord compression. Patients with unstable untreated brain or meningeal metastases are not eligible
    16. Inability to attend or comply with treatment or follow-up scheduling
    17. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
    18. Fertile women of childbearing potential not willing to use adequate contraception for the duration of trial treatment and at least 6 months after
    19. Any other severe uncontrolled medical condition or disease
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Royal Free Hospital
London
NW1 2BU
Trial Contact(s)
Primary Trial Contact
Prof Jonathan Ledermann
Other Trial Contacts
Ms Liz Clark
-
Countries Recruiting
Australia, Canada, New Zealand, Spain, United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
A double-blind, placebo-controlled, three-arm, randomised, multi-centre Gynaecologic Cancer InterGroup trial of cediranib (AZD2171), in combination with platinum-based chemotherapy and as a single agent maintenance therapy, in women with ovarian cancer relapsing more than 6 months following completion of first-line platinum-based treatment
EudraCT Number
2007-001346-41
Funder(s)
  • Cancer Research UK (ref: C444/A6862)
  • AstraZeneca (ref: D8480C00037) (International)
  • Medical Research Council
  • National Health and Medical Research Council
Other Study ID Numbers
N/A
Sponsor(s)
Medical Research Council (UK)
Key Dates

Recruitment Start Date

29 Nov 2007

Recruitment End Date

23 Dec 2011

Trial Start Date

01 Jul 2007

Trial End Date

31 Dec 2016

Date Assigned

13 Aug 2007

Last Updated

31 Mar 2016